Cook Medical Leads $52M Zenflow Financing For BPH Device

Zenflow, Inc. announced on October 5, 2026, that it closed an oversubscribed $52 million Series D financing round led by Cook Medical. Zenflow also announced an exclusive U.S. distribution agreement with Cook Medical for the Zenflow Spring® System, an FDA-approved device for men with benign prostatic hyperplasia (BPH), commonly called enlarged prostate.

This is a corporate financing and distribution announcement, not a lawsuit, settlement or recall. No claim form, settlement or compensation program exists, and patients do not need to file anything.

Zenflow and Cook Medical Financing Quick Facts

Detail	Information
Companies	Zenflow, Inc. (South San Francisco, California) and Cook Medical
Financing	$52 million Series D, described as oversubscribed
Announced	October 5, 2026
Lead investor	Cook Medical
Other investors named	ClavystBio (new), Invus Opportunities, F-Prime, Medtech Venture Partners and others
Venture debt	HSBC Bank USA, N.A. and Trinity Capital
Use of proceeds	To accelerate commercial launch after FDA approval
Distribution	Exclusive U.S. distribution agreement with Cook Medical
Device	Zenflow Spring® Implant and Delivery System
Condition	Benign prostatic hyperplasia (BPH)
FDA approval	Premarket approval (PMA) P250007, decision date December 11, 2025
FDA application received	March 11, 2025
Lawsuit or settlement	None identified
Official settlement website, claim form or deadline	None. Not applicable

What the Financing Means

According to Zenflow, the Series D proceeds will support the commercial launch of the Spring System following FDA approval. Cook Medical, which has an established presence in urology, will distribute the device in the United States under an exclusive agreement. Zenflow said Cook had also invested in the company earlier.

The company described the arrangement as a way to bring the device to urologists and patients nationwide. The announcement did not give a nationwide availability date. A September 2026 company update said the first commercial procedures had been completed at four centers, so availability is still limited.

What the FDA Approved

The FDA’s record lists the Zenflow Spring Implant and Delivery System under PMA P250007, with Zenflow, Inc. as the applicant. The FDA approval order states the device is indicated for treating obstructive lower urinary tract symptoms secondary to BPH in men with prostatic urethral lengths between 25 and 45 mm and prostate sizes between 25 and 80 cc.

That indication matters. FDA approval is a regulatory decision about the device’s authorized use. It does not mean the device is suitable for every man with BPH, and it is not a guarantee of any individual result.

A PMA is the FDA’s most rigorous review pathway and applies to higher-risk devices. The FDA also lists a post-approval study for this device, which means follow-up on the approved product continues after approval.

What Is BPH?

BPH occurs when the prostate gland enlarges and presses on the urethra, the tube that carries urine out of the body. Common symptoms include difficulty starting urination or emptying the bladder, a weak or interrupted stream, frequent or urgent urination and nighttime urination.

What Zenflow Says About the Device

Zenflow describes the Spring System as an in-office treatment with sizing options that is reversible if desired. The company also says the device offers advantages including no post-procedure catheter and preservation of sexual function.

These are the company’s statements, not FDA findings. Patients should rely on the FDA-approved labeling and their urologist for the device’s risks, contraindications and suitability.

Cook Medical Leads $52M Zenflow Financing as FDA-Approved BPH Device Moves Toward US Commercial Launch

Is There a Lawsuit or Settlement?

No. No lawsuit, settlement administrator, class-action notice, claim form or deadline connected to this announcement was identified. Patients do not need to file a claim because of the financing or the FDA approval.

If someone believes a medical device caused them harm, that is a separate legal question. A possible product-liability claim depends on the specific facts, including the device, medical records, what caused the injury and the law of the state involved.

What Patients Considering the Spring System Should Do

No legal filing is needed. Anyone considering treatment can:

Ask a urologist whether this device is appropriate for their condition and anatomy.
Ask whether their prostate size and prostatic urethral length fall within the FDA-approved indication.

Review the FDA-approved labeling, including contraindications, warnings and precautions.
Ask about alternatives, including medication and other BPH procedures.
Ask about risks and possible complications before consenting.
Keep medical records of any procedure, especially if an unexpected complication occurs.
Report any suspected device problem to the treating provider and to the FDA’s device reporting channels.

What Happens Next

Zenflow’s next step is commercialization, with Cook Medical handling U.S. distribution. On the regulatory side, the FDA’s post-approval study for the device continues. Patients and physicians should watch for updates in FDA labeling and safety communications.

Key Dates

Date	Event
March 11, 2025	FDA received Zenflow’s PMA application
December 11, 2025	FDA approved PMA P250007
December 19, 2025	FDA published the PMA notice
September 8, 2026	Zenflow reported first commercial procedures at four centers
October 5, 2026	Zenflow announced the $52 million Series D and the Cook Medical distribution agreement

Frequently Asked Questions

Did Cook Medical invest $52 million in Zenflow?

Zenflow announced an oversubscribed $52 million Series D round led by Cook Medical. Other investors participated, and HSBC Bank USA and Trinity Capital provided venture debt.

What is the Zenflow Spring System?

It is an FDA-approved implant and delivery system for treating obstructive lower urinary tract symptoms caused by BPH in men who meet the approved anatomical criteria.

Is the Zenflow Spring System FDA approved?

Yes. The FDA approved it under PMA P250007 on December 11, 2025.

Who will distribute it in the United States?

Cook Medical, under an exclusive distribution agreement announced October 5, 2026.

Can every man with BPH use it?

No. The FDA indication is limited to men with specific prostatic urethral lengths and prostate sizes, and a physician decides whether it is appropriate.

Is there a lawsuit, settlement or claim form?

No. None was identified.

Is the FDA still monitoring the device?

The FDA lists a post-approval study for this device, so follow-up continues after approval.

When will it be available everywhere in the U.S.?

Zenflow has not announced a nationwide availability date.

Sources

Zenflow, Inc., “Zenflow Secures $52M Series D Financing and Announces Exclusive U.S. Distribution Partnership with Cook Medical,” GlobeNewswire, October 5, 2026. https://www.globenewswire.com/news-release/2026/10/05/3374449/0/en/zenflow-secures-52m-series-d-financing-and-announces-exclusive-u-s-distribution-partnership-with-cook-medical.html
U.S. Food and Drug Administration, Premarket Approval (PMA) database, P250007. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250007
U.S. Food and Drug Administration, Post-Approval Studies database, Zenflow Spring (PMA P250007). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?tid=847855

About the Author

Israr Ahmad is a legal content researcher with 4+ years of experience covering class action settlements and consumer rights cases. He has researched and published coverage of 2,500+ settlements using verified court records, settlement administrator filings, and government sources. Learn more about Israr.

Cook Medical Leads $52M Zenflow Financing as FDA-Approved BPH Device Moves Toward US Commercial Launch